The Hair Growth Cycle: What It Is, How It Works, and Why It Matters for Hair Loss
Published by AmpleLab Research
Hair loss is usually discussed in terms of what causes it: DHT, genetics, stress, nutrition. What gets less attention is the underlying biology that those causes disrupt. Hair does not simply grow and fall out. It follows a precisely regulated cycle of growth, transition, rest, and shedding; and the way that cycle is disrupted, shortened, and eventually terminated is the actual mechanism of androgenetic alopecia.
Understanding the hair growth cycle properly changes how you think about hair loss treatments, what they're trying to do, and why some approaches work better than others. This article covers the biology in detail.
The hair follicle is a complex mini-organ embedded in the dermis and hypodermis of the scalp. Each follicle is a self-contained unit capable of producing hair indefinitely, provided it remains healthy. The average scalp contains approximately 100,000 follicles, and each will cycle through growth and rest phases many times over a lifetime.
The most important structure within the follicle is the dermal papilla: a cluster of specialised mesenchymal cells at the base of the follicle that acts as the primary signalling centre for the growth cycle. The dermal papilla communicates with the matrix cells above it, instructing them to proliferate and differentiate into the cells that form the hair shaft. It is the dermal papilla that responds to androgens in androgenetic alopecia, and it is the target of most hair growth research.
Also important is the bulge region, located in the upper portion of the follicle. The bulge contains adult stem cells that replenish the lower follicle at the start of each growth cycle. If the stem cell population in the bulge is depleted or damaged, the follicle loses its ability to cycle, which is thought to be a feature of late-stage follicle loss in androgenetic alopecia.
The hair growth cycle consists of four phases: anagen, catagen, telogen, and exogen. Each phase has a distinct biology, and the balance between them determines both hair density and shedding rate at any given time.
Anagen is the active growth phase. During anagen, matrix cells in the lower follicle divide rapidly and differentiate into the cells that form the hair shaft, which is pushed upward through the scalp at a rate of approximately 1cm per month. On a healthy scalp, 85 to 90 percent of follicles are in anagen at any given time.
Anagen duration is genetically determined and varies significantly between individuals, typically lasting between two and seven years on the scalp. This duration is the primary reason some people can grow their hair very long while others cannot: it is not a difference in growth rate but in how long the follicle sustains active growth before cycling into rest. In androgenetic alopecia, anagen duration progressively shortens with each cycle, producing shorter, finer hairs.
Catagen is a brief transitional phase lasting approximately two to three weeks. The lower follicle undergoes controlled regression: the matrix cells stop dividing, the follicle detaches from its blood supply, and the dermal papilla condenses and moves upward toward the bulge. Only around one to three percent of scalp follicles are in catagen at any given time. Catagen is not directly affected by androgens, but its timing is influenced by signals from the dermal papilla, meaning that androgen-disrupted papilla function can alter how smoothly the transition is executed.
Telogen is the resting phase, lasting three to four months on the scalp. The follicle is dormant; the hair shaft is retained but not growing. Approximately ten to fifteen percent of scalp follicles are in telogen at any one time. The telogen hair, sometimes called a club hair because of its distinctive club-shaped root, is eventually dislodged by the emergence of the new anagen hair growing beneath it.
Telogen effluvium, a common cause of diffuse hair shedding, occurs when a significant proportion of follicles are simultaneously pushed into telogen, typically by a systemic trigger such as illness, surgery, nutritional deficiency, or major physiological stress. The resulting shed occurs two to four months after the trigger, which is why the connection between cause and effect is frequently missed.
Exogen is sometimes treated as part of telogen and sometimes described as a distinct fourth phase. It refers specifically to the active shedding of the telogen hair shaft, which involves enzymatic activity in the follicle rather than simply passive mechanical release. Losing 50 to 100 hairs per day is considered within the normal range for a healthy scalp cycling through exogen; significant deviation from this, particularly with visible thinning, warrants attention. The exogen phase is followed immediately by the onset of a new anagen cycle in a healthy follicle.
Cycle at a Glance
Androgenetic alopecia (pattern hair loss) is not simply the death of hair follicles, though that can occur in late-stage disease. It is primarily the progressive disruption of the hair growth cycle, driven by the interaction of dihydrotestosterone (DHT) with androgen receptors in the dermal papilla.
DHT is produced from testosterone by the enzyme 5-alpha reductase (5-AR). In genetically susceptible follicles, DHT binding to androgen receptors in the dermal papilla triggers a cascade of signalling changes that progressively shorten anagen duration. Each cycle, anagen lasts a little less long; the resulting hair shaft is a little shorter and thinner. Over repeated cycles, the follicle miniaturises: the hair it produces becomes so fine and short that it is effectively invisible, while the follicle itself shrinks closer to the surface of the scalp.
A feature of androgenetic alopecia that is sometimes underemphasised is perifollicular fibrosis: the gradual accumulation of fibrous tissue around the follicle, which compresses its blood supply and restricts the environment the follicle needs to cycle. This is not simply a consequence of follicle miniaturisation; it is increasingly understood as an active component of the disease process. Follicles with significant perifollicular fibrosis are generally thought to be less responsive to treatment even if DHT is addressed, which is one reason that early intervention tends to produce better outcomes than late intervention.
The anagen:telogen ratio is a useful clinical indicator of scalp health. On a healthy scalp the ratio is roughly 9:1. In progressive androgenetic alopecia, as more follicles miniaturise and spend shorter periods in anagen, the ratio shifts toward more telogen follicles, which manifests as increased shedding and reduced density before visible thinning becomes obvious to the naked eye.
Understanding the cycle clarifies what any hair loss intervention is actually trying to achieve. There are broadly four targets:
Finasteride and dutasteride reduce DHT by inhibiting 5-alpha reductase, slowing or halting the miniaturisation process. They address the androgen signal at source. Their limitation is that they are systemic: they reduce DHT throughout the body, not only at the scalp, which underlies their side effect profile.
Minoxidil is thought to act partly through potassium channel opening in follicle cells, which promotes anagen entry and prolongs the growth phase. Copper peptides, particularly AHK-Cu (1%), have been investigated for their ability to stimulate follicle keratinocyte proliferation and support follicle survival in early-stage laboratory models, which is consistent with anagen-supporting activity.
An adequate blood supply around the follicle is necessary for the metabolic demands of active anagen growth. Minoxidil promotes vasodilation; VEGF-upregulating compounds, including 2-Deoxy-D-Ribose (2% 2dDR) and GHK-Cu (1%), are associated with angiogenic activity in preclinical models. Supporting the perifollicular microenvironment, particularly its vascular component, is a complementary approach to directly addressing DHT.
Chronic low-grade perifollicular inflammation and the associated fibrosis are now considered active components of androgenetic alopecia rather than passive consequences of it. Anti-inflammatory topical actives, including GHK-Cu which has been associated with downregulation of pro-inflammatory cytokines in cell culture models, may address this component of the disease environment alongside vascular and follicle-stimulating interventions.
The hair growth cycle has a practical implication that often surprises people: any topical treatment takes time to register a visible effect, even if it is working.
A follicle currently in telogen when you start a treatment will not respond until it re-enters anagen, which may be three to four months away. A follicle in early anagen will produce a hair that takes months to reach visible length. The commonly cited benchmark of six months before evaluating a topical hair loss treatment is grounded in cycle biology: it takes that long for a meaningful proportion of follicles to have cycled through a new anagen phase under the influence of the treatment.
An initial increase in shedding after starting a new treatment is also a known phenomenon. It can reflect the displacement of telogen hairs by new anagen growth entering the follicle, which is a positive rather than a negative signal. It can also reflect other causes entirely. The important point is that early shedding alone is not a reliable indicator of treatment failure.
Realistic Timelines
Minimum assessment period: 3 to 4 months for any cycle-related change to become apparent
Meaningful assessment period: 6 to 12 months for a reliable picture of treatment response
Early increased shedding: common in first 4 to 8 weeks; not necessarily a negative signal
How many times does a follicle cycle in a lifetime?
A scalp follicle is thought to have a finite number of cycles over a lifetime, though precise estimates vary; figures of a few dozen cycles are commonly cited in the literature. This finite capacity can be reduced by damage, disease, or significant nutritional deficiency. It is one reason that very late-stage hair loss, where follicles have cycled many times under androgenic stress, is harder to reverse than early-stage loss where follicle cycling capacity is better preserved.
Is it possible to reactivate a dormant follicle?
It depends on the state of the follicle. A follicle in telogen or a miniaturised but still cycling follicle may respond to treatment. A follicle where the dermal papilla has been replaced by fibrous tissue and the stem cell population in the bulge is depleted is unlikely to be reactivated by topical interventions. This is why dermatologists generally assess follicle viability, often via trichoscopy or biopsy, before predicting treatment response.
Does hair grow at the same rate across the scalp?
Broadly yes, at approximately 1cm per month, though individual variation exists and growth rate slows slightly with age. What differs across the scalp in androgenetic alopecia is not growth rate but anagen duration and follicle calibre; follicles in androgen-sensitive areas cycle through shorter anagen phases, producing shorter, finer hairs even when growing at the same rate per day.
Why is shedding worse in autumn?
There is some evidence that telogen rates are mildly higher in autumn months, with a corresponding anagen peak in spring and summer. The mechanism is not fully established in humans, though it may reflect vestigial seasonal photoperiod responses similar to those seen more strongly in other mammals. The pattern is subtle and individual variation is high; it does not represent a clinical concern in the absence of other symptoms.
How does microneedling interact with the hair growth cycle?
Microneedling creates controlled micro-injury in the scalp, which triggers a wound-healing response including growth factor release and increased blood flow. There is evidence from small clinical studies that this can promote anagen entry, possibly by activating stem cells in the bulge region via the wound-healing signal, though the mechanism in humans is not fully established. It also increases the absorption of topically applied actives, which is why glycol-free serums are preferred for use alongside microneedling protocols.
This article is provided for educational purposes. AmpleLab products are cosmetic formulations and are not intended to diagnose, treat, cure, or prevent any condition.
AmpleLab.